Halozyme Therapeutics HALO Total debt
Total debt at other companies
Other financials
Where this comes from
Calculated from Halozyme Therapeutics’s reported figures.
Plus components not separately reported this period.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's total debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's total debt?
- Halozyme Therapeutics (HALO) reported total debt of $2.18B in Q1 2026.
- How has Halozyme Therapeutics's total debt changed year-over-year?
- Halozyme Therapeutics's total debt increased by 41.7% year-over-year, from $1.54B to $2.18B.
- What is the long-term trend for Halozyme Therapeutics's total debt?
- Over 5 years (2020 to 2025), Halozyme Therapeutics's total debt has grown at a 40.2% compound annual growth rate (CAGR), from $402.1M to $2.18B.
- What does total debt mean?
- Total debt is the combined amount of all interest-bearing loans, leases, and financial obligations a company owes to external parties.
- How do you interpret total debt?
- An increase in total debt suggests higher financial leverage and potential interest expense pressure, while a decrease indicates deleveraging or debt repayment. High levels relative to cash flow may signal increased financial risk, whereas lower levels often indicate a stronger balance sheet.
- How does total debt compare across companies?
- Peer companies in the biotechnology sector typically maintain lower debt levels compared to capital-intensive industries, often prioritizing cash reserves for R&D and clinical trials.